The addition of iniparib also prolonged the median progression-free survival from 3.6 months to 5.9 months ( hazard ratio for progression , 0.59 ; P = 0.01 ) and the median overall survival from 7.7 months to 12.3 months ( hazard ratio for death , 0.57 ; P = 0.01 ) .
